Leukoencephalopathy in Patients with Brain Metastases Who Received Radiosurgery With or Without Whole Brain Radiotherapy

doi:10.21203/rs.3.rs-1982361/v1

Download PDF

Research Article

Leukoencephalopathy in Patients with Brain Metastases Who Received Radiosurgery With or Without Whole Brain Radiotherapy

https://doi.org/10.21203/rs.3.rs-1982361/v1

This work is licensed under a CC BY 4.0 License

You are reading this latest preprint version

Background

Whole brain radiation therapy (WBRT) for brain metastases (BMs) is a common cause of radiation-induced leukoencephalopathy; however the safety of alternative stereotactic radiosurgery (SRS) remains unclear. This study examined the incidence of leukoencephalopathy in patients treated with SRS alone versus WBRT plus SRS for BMs with a focus on the relationship between prognostic factors and leukoencephalopathy.

Methods

Analysis was performed between 2002 and 2021. The total enrollment was 993 patients with the distribution: WBRT plus SRS (n=291) and SRS only (n=702). Leukoencephalopathy was graded from 0 to 3 for changes in white matter indicated by the MRI after WBRT or SRS. Patient characteristics and SRS dosimetric parameters were reviewed to identify factors that contributed to the incidence of leukoencephalopathy or overall survival.

Results

The incidence of leukoencephalopathy was consistently higher in WBRT plus SRS group than in SRS alone group (p＜0.001). Leukoencephalopathy was also associated with a larger total tumor volume (≧28cm³; p=0.028) and age (＞77 years; p=0.025). Nonetheless, the SRS integral dose to skull in the subgroup of WBRT plus SRS treatment was not demonstrated significance in development of leukoencephalopathy (p=0.986 for integral dose 1-2J, p=0.776 for integral dose＞2J).

Conclusions

This study revealed that SRS is safe for oligo-BMs in terms of leukoencephalopathy development. Patient age and total tumor volume were identified as important factors in assessing the development of leukoencephalopathy. The additional of SRS (even at an integral dose＞2J) did not increase the incidence of leukoencephalopathy.

brain metastasis

stereotactic radiosurgery

gamma knife radiosurgery

whole brain radiotherapy

leukoencephalopathy

Approximately 30% of patients with cancer develop brain metastases (BMs) [1, 2]. Whole brain radiation therapy (WBRT) has long been the standard treatment for intracranial metastases [3, 4]; however, this has raised concerns pertaining to physical side effects (changes in white matter; leukoencephalopathy) and radiation-induced neurocognitive dysfunction [5, 6]. This has led to the development of an alternative treatment involving stereotactic radiosurgery (SRS).

The safety of SRS in treating BMs has been assessed in two retrospective studies. Those works revealed that the risk of developing progressive radiation-induced leukoencephalopathy was lower for patients who underwent SRS than among those who underwent WBRT in conjunction with SRS [7, 8]. They identified a number of risk factors for radiation-induced leukoencephalopathy, including total tumor number, total tumor volume, and integral doses; however, there were a number of inconsistencies between the papers. Our objective in the current study was to compare the incidence of leukoencephalopathy between patients treated using SRS alone or WBRT plus SRS for BMs. We also sought to identify the dosimetric parameters and prognostic factors associated with leukoencephalopathy.

Patient population

This retrospective study included all patients (n = 933) who received SRS or WBRT as the initial treatment for BMs between 2002 and 2021. Among those patients, 291 patients received WBRT plus SRS whereas 702 received SRS alone. Eligibility criteria included newly diagnosed BMs at the time of the first SRS or WBRT session, pathologic confirmation of extracerebral tumor site (e.g., lung or breast) from either the primary site or a metastatic lesion, and no contraindications for magnetic resonance imaging (MRI). Exclusion criteria included previous treatment for nonmetastatic brain disease, any contraindication to MRI, unavailable follow-up clinical records or imaging studies, or a history of a demyelinating disorder such as multiple sclerosis. The institutional review board approved the current study prior to initiation and written informed consent was obtained from each patient.

SRS treatment

SRS treatment was performed using a Leksell Gamma Knife (model 3C or 4C) with a ⁶⁰Co sources in conjunction with a Perfexion radiosurgery unit (Elekta Instruments) in a single session. Radiosurgery plans were created using Leksell Gamma Plan software and reviewed by a neurosurgeon, radiation oncologist, and medical physicist prior to radiosurgery. The median margin dose was 19 Gy (range 11–30 Gy) and the median radiation volume was 2.29 cm³ (range 0.01–57.94 cm³). The isodose line around the tumor was between 45% and 90% of the maximum dose. Patients who underwent WBRT received a median margin dose of 30 Gy (range 16.7–44.4 Gy) administered over a median of 14 fractions [9]. None of the patients in this series underwent a second course of WBRT.

Clinical presentation and neuroimaging assessments

Prior to registration, each patient was assessed in terms of medical history, physical condition, and neurological condition. MRIs were performed at the time of SRS or WBRT and at least once as a follow-up. Clinical data were obtained for all eligible patients, including age, sex, histology and primary site of tumors, extracranial disease, and Karnofsky performance status (KPS) as well as previous treatments, including systemic anti-cancer medication or craniotomy. After treatment, SRS-related toxicity, WBRT dose and fractionation, tumor volume, tumor location, SRS dosage, integral dose to the brain, and survival were recorded.

All patients underwent MRI follow-ups at 3-month intervals. All MRI scans (T1-weighted [T1W], T2-weighted [T2W], and contrast-enhanced T1W images) were reviewed by the same group of investigators with a focus on changes in cerebral white matter, local tumor control, distant tumor control, and radiation necrosis. In some situations, it is preferable to use FLAIR sequences to identify changes in periventricular white matter, as the sensitivity is higher than that of T2 sequences [10]. We employed a simplified grading system, which has been clinically validated [11–14], for the detection of changes in cerebral white matter. Under this grading system, T2 sequences are categorized as follows: grade 0 (normal), grade 1 (mild changes in periventricular white matter), grade 2 (moderate changes in periventricular white matter), and grade 3 (severe and/or diffuse changes in white matter) (Fig. 1) [15, 16]. Perifocal edema associated with a brain metastasis was not included in this assessment. Leukoencephalopathy is by definition diffuse and periventricular, compared to perifocal edema associated with tumors.

Statistical analysis

Median or mean and range were used for continuous variables while frequency and percentages were used for categorical variables. The Kaplan-Meier method was used to assess overall survival (OS) and the incidence of leukoencephalopathy. OS was defined as the time from the first clinical visit until death or the last clinical follow-up visit. The incidence of leukoencephalopathy was defined as the time from the MRI scan associated with the first SRS or WBRT session to the last follow-up MRI scan. OS and the incidence of leukoencephalopathy were compared between the groups (SRS alone versus WBRT plus SRS). Cox regression univariate and multivariate analyses were performed to characterize the correlation potential prognostic indicators (age, sex, KPS, number of metastatic lesions, total tumor volume, extracranial metastasis, baseline leukoencephalopathy, SRS integral dose to the cranium, WBRT, surgical resection, and chemotherapy) and survival or leukoencephalopathy. The Cox proportional hazards model was used to calculate hazard ratios and 95% confidence intervals. Multivariate analysis was used to assess prognostic factors with significance of less than 0.05 in univariate analysis. All statistical analysis was performed using SPSS version 25.0 (SPSS Inc, Taipei, Taiwan).

Clinical presentation

A total of 993 patients were included in the cohort for analysis (Table 1). The median survival time among the cases of mortality was as follows: SRS alone (13.2 months; range 0.7-151.6 months) and SRS plus WBRT (16.9 months; range 1.6-109.1 months) (p = 0.740). The median follow-up period was as follows: SRS alone (14.5 months; range 0.1-177.7 months) and SRS plus WBRT (18.4 months; range 0.2-233.2 months). The median imaging follow-up period was as follows: SRS alone (11.9 months; range 0.1-177.7 months) and SRS plus WBRT (15.8 months; range 0.1-233.2 months) (p = 0.951). The median age was as follows: SRS alone (62.5 years) and SRS plus WBRT (58.1 years) (p = 0.034). The median SRS tumor margin dose was as follows: SRS alone (18 Gy) and SRS plus WBRT (18 Gy). The median total tumor volume was as follows: SRS alone (2.26 mL) and SRS plus WBRT (2.41 mL) (p = 0.189). In the SRS and SRS plus WBRT groups, respectively, the most common origin of BMs was lung cancer (73.2% vs 75.3%) and the most common location of BMs was the frontal lobe (30.9% vs 28.4%), followed by parietal lobe (17.1% vs 15.8%) and cerebellum (15.45% vs 21.8%). We observed no statistical difference between the two groups in terms of median KPS score (p = 0.901).

Table 1

Clinical characteristics of the 993 patients included in the study
	SRS alone (n = 702)		WBRT + SRS (n = 291)
Characteristic	Value*	Percentage or Range	Value*	Percentage or Range
Sex (male:female)	332:370	47.29%:52.71%	113:178	39.83%:61.17%
Age (yrs) mean	62.50	15.70–93.10	58.10	18.30–89.00
Median max tumor vol (ml)	0.16	0.01–48.20	0.19	0.01–38.41
Median total tumor vol (ml)	2.26	0.01–57.94	2.41	0.01–38.43
Intracranial metastases
1 (single lesion)	264	37.61%	96	32.99%
2	161	22.93%	51	17.53%
3	101	14.39%	47	16.15%
> 3	176	25.07%	97	33.33%
Total number of intracranial metastases	2065		945
Tumor location (n)
Frontal	639	30.94%	268	28.36%
Parietal	352	17.05%	149	15.77%
Cerebellum	319	15.45%	206	21.80%
Temporal	238	11.53%	110	11.64%
Occipital	267	12.93%	92	9.74%
Basal ganglia/thalamus	67	3.24%	34	3.60%
Brainstem	35	1.69%	11	1.16%
Insula	20	0.97%	10	1.06%
Other	128	6.20%	65	6.88%
Extracranial metastasis	336	47.86%	127	43.64%
KPS score (median)	90	50–100	90	50–100
Neurological deficits
Long-tract signs	145	20.66%	60	20.62%
Cerebellar signs	65	9.26%	33	11.34%
Cranial nerve palsy	71	10.11%	33	11.34%
High cortical dysfunction	30	4.27%	12	4.12%
Asymptomatic	449	63.96%	180	61.86%
Histologic type
Lung	514	73.22%	219	75.26%
Breast	61	8.69%	45	15.46%
Renal	24	3.42%	4	1.37%
Colorectal	17	2.42%	9	3.09%
Ovarian	7	1.00%	1	0.34%
Liver	7	1.00%	1	0.34%
Esophageal	7	1.00%	1	0.34%
Other	65	9.26%	11	3.78%
Prior craniotomy	94	13.39%	61	20.96%
Prior chemotherapy	71	10.11%	20	6.87%
Leukoencephalopathy (n)
Grade 0	669	95.30%	124	42.61%
Grade 1	13	1.85%	48	16.49%
Grade 2	6	0.85%	32	11.00%
Grade 3	14	1.99%	87	29.90%
Imaging follow-up period (mos)	11.93	0.13-177.67	15.77	0.10-233.21
Clinical follow-up period (mos)	14.49	0.13-177.67	18.39	0.20-233.21
Median survival (mos) death only^#	13.21	0.72-151.57	16.92	1.64-109.11
SRS protocol†
Radiation volume (ml)	0.61	0.02–55.80	0.83	0.01–43.24
Margin dose (Gy)	18	11.00–30.00	18	11.00–26.00
Max dose (Gy)	30.83	18.90–50.00	30	16.70–44.40
Isodose level (%)	60	40.00–95.00	62	45.00–96.00
Abbreviations: KPS, Karnofsky Performance Status; SRS, stereotactic radiosurgery; WBRT, whole-brain radiation therapy. *Data are expressed as number of patients or median value, unless otherwise noted. #This category excluded patients who survived the entire study. A total of 434 patients were excluded and 559 patients (357 patients with SRS alone and 202 patients with WBRT + SRS) were evaluated for median survival time. The range of median survival time was calculated in the SRS alone and WBRT + SRS groups. † All patients in the study underwent at least one SRS procedure. The dose was determined by the integral dose to the brain and prescribed to the highest isodose line encompassing the target. The integral dose was calculated as the product of the mean dose to the outer head contour and the outer head contour volume.

The Incidence of Leukoencephalopathy

In Fig. 2, the incidence of leukoencephalopathy is illustrated as a function of time or specific grade. The incidence of leukoencephalopathy in the WBRT plus SRS group increased gradually, as follows: 1st follow-up (18.2%), 2nd follow-up (33.7%), and 3rd follow-up (50.5%). Patients who underwent WBRT experienced leukoencephalopathy of higher severity with a more abrupt onset. More than 96% of the patients who underwent SRS alone remained free from leukoencephalopathy (grade 0) after a 4-year follow-up.

The overall incidence of leukoencephalopathy was 20.1%. The overall cumulative incidences of leukoencephalopathy after radiotherapy treatment were as follows: 7.9% (1-year), 21.2% (2-year), 34.7% (3-year), 44.4% (4-year), and 50.5% (5-year) (Fig. 3A). The cumulative incidence of leukoencephalopathy was higher in the WBRT plus SRS group than in the SRS alone group: 1-year (19% vs 2.6%), 2-year (45.9% vs 5.3%), 3-year (67.5% vs 7.8%), 4-year (79.1% vs 11.2%), and 5-year (85% vs 14.7%) (p＜0.001) (Fig. 3B).

Prognostic factors for leukoencephalopathy

The prognostic factors for the incidence of leukoencephalopathy are listed in Table 2. WBRT treatment had a significant influence on the likelihood of developing leukoencephalopathy (p＜0.001) (Table 2 and Fig. 3B). Age (p = 0.025 and p＜0.001) was also associated with an elevated incidence of leukoencephalopathy (Fig. 3C). Finally, a larger total tumor volume was correlated with the incidence of leukoencephalopathy (Fig. 3D), particularly in larger tumors ( ≧ 28cm³; p = 0.028 and p＜0.001). Pre-SRS chemotherapy (p = 0.02 and 0.166) and the total number of metastases (p = 0.008 and 0.303) were weakly and significantly correlated in univariate analyses but not significant in multivariate analyses. Other prognostic factors, including sex, extracranial metastasis, and tumor resection, presented no significant correlation with leukoencephalopathy.

Table 2

Correlations between prognostic factors and survival or the development of leukoencephalopathy after radiotherapy
Factors	Incidence of leukoencephalopathy^#						Overall survival
	Univariate analysis			Multivariate analysis			Univariate analysis			Multivariate analysis
	HR*	95% CI	P value	HR*	95% CI	P value	HR*	95% CI	P value	HR*	95% CI	P value
Age (＞77 y/o vs. ≦77 y/o)	1.718	1.069–2.760	0.025†	2.971	1.826–4.835	< 0.001†	1.539	1.161–2.040	0.003†	1.605	1.203–2.142	0.001†
Sex (M:F)	0.830	0.623–1.106	0.204				1.192	1.010–1.408	0.038†	1.283	1.083–1.521	0.004†
Extracranial metastasis (Yes vs. No)	1.313	0.993–1.736	0.056				1.301	1.101–1.538	0.002†	1.297	1.093–1.538	0.003†
Pre-SRS tumor resection (Yes vs. No)	1.406	0.989–1.999	0.058				0.876	0.686–1.119	0.290
Pre-SRS chemotherapy (Yes vs. No)	1.742	1.092–2.781	0.020†	1.397	0.871–2.240	0.166
Total No. of metastatic lesions (n = lesion number)
n=1	Ref.			Ref.			Ref.			Ref.
n ≧ 2	1.498	1.110–2.021	0.008†	1.172	0.866–1.587	0.303	1.193	1.003–1.418	0.046†	1.170	0.980–1.393	0.079
Total tumor volume (cm³)
Tumor＜14 cm³	Ref.			Ref.			Ref.			Ref.
14 cm³ ≦ Tumor＜28 cm³	1.054	0.587–1.890	0.861	1.164	0.646–2.097	0.613	1.319	0.966–1.801	0.082	1.272	0.930–1.738	0.132
Tumor ≧ 28 cm³	3.045	1.124–8.247	0.028†	6.271	2.258–17.411	< 0.001†	2.287	1.255–4.165	0.007†	2.111	1.150–3.875	0.016†
SRS ± WBRT (Yes vs. No)	11.007	7.573–15.999	< 0.001†	11.969	8.183–17.506	< 0.001†	1.260	1.060–1.498	0.009†	1.291	1.083–1.540	0.004†
KPS score (＜80 vs. ≧80)							1.535	1.185–1.988	0.001†	1.458	1.118–1.902	0.005†
Abbreviations: HR, Hazard ratio; SRS, stereotactic radiosurgery; WBRT, whole-brain radiation therapy; M: F, male: female; Ref., reference.
* Hazard ratio was modeled using univariable and multivariable cox proportional hazards regression models.
#Leukoencephalopathy includes any grade above baseline.
† Statistically significant.

Subgroup analysis was used to evaluate the dosimetric effects of WBRT or SRS on leukoencephalopathy. In the SRS alone group, the total number of metastatic lesions, total tumor volume, and integral dose to the skull were not significantly correlated with the incidence of leukoencephalopathy (Supplementary Table 1, Fig. 3F). In the WBRT plus SRS group, a higher total tumor volume was correlated with the incidence of leukoencephalopathy, particularly in larger tumors ( ≧ 28cm³; p＜0.001) (Supplementary Table 2, Fig. 3E). Dose plan and integral dose were not correlated with the occurrence of leukoencephalopathy

Overall, WBRT was the most important factor in the development of leukoencephalopathy, followed by patient age and total tumor volume.

Overall survival

The overall survival (OS) rate of all patients was 43.7%. The cumulative survival rates decreased gradually as a function of time after radiotherapy treatment, as follows: 1-year (73.3%), 2-year (51.2%), 3-year (38.5%), 4-year (29.4%), and 5-year (23.7%) (Fig. 4A). Age, sex, extracranial metastasis, total tumor volume, WBRT, and KPS were significantly correlated with OS (Table 2 and Fig. 4B-G).

The median survival was as follows: WBRT plus SRS (24.2 months) and SRS alone (25.4 months). The OS in the WBRT plus SRS group varied as a function of time, as follows: 1-year (70.3%), 2-year (50.4%), 3-year (32.9%), 4-year (23.2%), and 5-year (15.4%). The OS in the SRS alone group also varied with time: 1-year (74.5%), 2-year (51.4%), 3-year (41.5%), 4-year (33.0%), and 5-year (28.8%). At any given time, the OS in the SRS alone group was higher than that in the WBRT plus SRS group (p = 0.009) (Fig. 4F). The factor analysis is detailed in Supplementary Tables 1 and 2.

In this study, WBRT (in conjunction with SRS) was shown to increase the incidence of leukoencephalopathy compared to SRS alone, while reducing OS rates. These results were in line with those in most previous studies [5, 6]. Note however that the SRS integral dose to the skull presented a non-significant correlation to the development of leukoencephalopathy in both subgroups, which indicated that WBRT is a major factor affecting the onset of leukoencephalopathy. Note also that two relatively small retrospective studies (n = 103 and 92) reported that SRS was associated with a reduced risk of developing leukoencephalopathy [7, 8]. SRS provided focal high radiation energy without inducing changes in white matter. To the best of our knowledge, this is the first large-scale study to demonstrate that SRS is safe in terms of leukoencephalopathy development following radiation therapy for BMs.

Concerns related to the side effects of WBRT and radiation-induced neurocognitive dysfunction have prompted several research groups to identify the prognostic factors for radiation-induced leukoencephalopathy, including WBRT dose and fractionation, the number of tumors, tumor size, total tumor volume and location, SRS prescription and integral dose to the brain [17–19]. The most important factor in selecting WBRT or SRS has been the numbers of tumors, followed by tumor size, cumulative brain burden, extracranial disease status, and radiotherapeutic dosimetry [20]. Note however that the conclusions in previous studies have been inconsistent with regard to the cutoff number of tumors in selecting SRS or WBRT more likely due to the number of tumors which is not major factors for evaluation of radiation-induced neurocognitive dysfunction. Thus, most previous studies dealing with the complications of radiosurgery have focused on extracranial disease status, brain tumor burden, the number of tumors, neurocognitive dysfunction, or quality of life [9, 21, 22]. One recent study identified tumor volume as a prognostic factor in cases where multiple BMs were treated using SRS [22]. Total tumor volume has also been identified as a significant predictor of radiation toxicity; however, it has seldom been considered in studies on the complications of radiosurgery [18, 23]. In the current study, total tumor volume was positively correlated with the development of leukoencephalopathy, particularly in cases where the total tumor volume exceeded 28 cm³ (Table 2). Therefore, the total tumor volume could be regarded as an important prognostic factor to evaluate radiation-induced leukoencephalopathy.

Note that 33 patients in the SRS alone group developed leukoencephalopathy, 15 of whom developed leukoencephalopathy before undergoing SRS treatment (Fig. 2). Although the pathophysiology of leukoencephalopathy was not totally understood [24, 25], age was thought to be a prognostic factor related to the development leukoencephalopathy in this study (Table 2 and Fig. 3C). Leukoencephalopathy is not uncommon among cancer patients undergoing chemotherapy (e.g., methotrexate, fluorouracil, or fludarabine) [26]. Leukoencephalopathy secondary to endothelial damage has also been shown to induce the breakdown of the blood-brain barrier, vasculitis, or demyelination [24, 25, 27]. Above hypotheses had been clinically indicated by evidence demonstrating that impaired glycemic control, and uncontrolled hypertension were important risk factors for endothelial damage.^{24, 25, 27} Thus, it appears that these clinical factors cannot be omitted when we attempt to conclude the occurrence of leukoencephalopathy in cancer patients.

This study was subject to a number of limitations. First, some of the BM patients who passed away early, showed no signs of leukoencephalopathy in follow-up MR images obtained prior to death. This very likely led us to underestimate the overall incidence of leukoencephalopathy and biased the incidence of leukoencephalopathy in the 3rd or 4th years (Fig. 2). Second, leukoencephalopathy was commonly identified in MRI scans obtained during routine follow-up, and time-to-event analyses of leukoencephalopathy were relied on when the events are identified. Therefore, we could not warrant whether the occurrence of leukoencephalopathy is at its on-set time or more severe grade. Third, patients in a poor clinical condition may have been treated using WBRT in accordance with the regulations of Taiwan’s National Health Insurance Administration, which stipulate cutoff KPS of ≧ 70 as the criteria for SRS payment. This probably introduced bias in our analysis of OS. Future studies on the safety of SRS should investigate neurocognitive function, quality of life, and adverse complications after SRS and WBRT.

This study demonstrated that BM patients who receive WBRT face an elevated risk of developing leukoencephalopathy. The use of SRS alone appears not to induce the occurrence of radiation-induced leukoencephalopathy. Age and total tumor volume were identified as important prognostic factors related to the development of leukoencephalopathy.

SRS= stereotactic radiosurgery; WBRT= whole brain radiotherapy; y/o= years old; Extra-meta= extracranial metastasis; KPS= Karnofsky Performance Status; TV= total tumor volume; Cumul incidence of leukoencephalopathy= cumulative incidence of leukoencephalopathy; No. at risk= number at risk; J= joules; BM= brain

Acknowledgments This work was financially supported by the Ministry of Science and Technology, Taiwan, under the project MOST 110-2314-B-075-038 -MY2 and MOST 111-2314-b-075-066. None of the authors have any conflicts of interest to declare.

Author contributions Conception and design: Liu, Lee; Literature search, articles screen, and data extraction: Yang, Chiang, Shen, Wu, Luo, Chen, Chao, Hu, Lin, Chung, Shiau, Guo, Pan, Lee; Analysis and interpretation of data: Liu, Lee; Writing—Review & Editing: Liu, Lee; Writing—Original Draft: Liu, Lee; Conceptualization and supervision: Lee; All authors read and approved the final manuscript.

Funding This study did not receive any funding support.

Data availability The authors confirms that data are available on reasonable requests.

Conflict of Interest This work was financially supported by the Ministry of Science and Technology, Taiwan. The authors declare that they have no known competing financial interests that could have appeared to influence the work reported in this paper.

Ethical approval No formal ethical approval was required for the research.

Consent to participate Not applicable.

Consent for publication Not applicable.

Nayak L, Lee EQ, Wen PY (2012) Epidemiology of brain metastases. Curr Oncol Rep 14:48–54. https://doi.org/10.1007/s11912-011-0203-y
Aoyama H, Shirato H, Tago M (2006) Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 295(21):2483–2491. https://doi.org/10.1001/jama.295.21.2483
Crossen JR, Garwood D, Glatstein E (1994) Neurobehavioral sequelae of cranial irradiation in adults: A review of radiation-induced encephalopathy. J Clin Oncol 12:27–642. https://doi.org/10.1200/JCO.1994.12.3.627
McDuff SG, Taich ZJ, Lawson JD (2013) Neurocognitive assessment following whole brain radiation therapy and radiosurgery for patients with cerebral metastases. J Neurol Neurosurg Psychiatry 84:1384–1391. https://doi.org/10.1136/jnnp-2013-305166
Melmer OCohen-InbarP, Lee Cheng-chia, Xu Z 1, Schlesinger D, Sheehan JP (2016) Leukoencephalopathy in long term brain metastases survivors treated with radiosurgery. J Neurooncol 126:289–298. https://doi.org/10.1007/s11060-015-1962-3
Daniel M, Trifiletti C-C, Lee D, Schlesinger JM, Larner Z, Xu JP, Sheehan (2015) Leukoencephalopathy After Stereotactic Radiosurgery for Brain Metastases. Int J Radiat Oncol Biol Phys 93(4):870–878. https://doi.org/10.1016/j.ijrobp.2015.07.2280
Brown PD, Jaeckle K, Ballman KV, Farace E, Cerhan JH, Anderson SK, Carrero XW, Barker FG II, Deming R, Burri SH (2016) Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. JAMA 316:401409. https://doi.org/10.1001/jama.2016.9839
Snell JW, Sheehan J, Stroila M, Steiner L (2006) Assessment of imaging studies used with radiosurgery: a volumetric algorithm and an estimation of its error. J Neurosurg 104(1):157–162. https://doi.org/10.3171/jns.2006.104.1.157
Griebe M, Forster A, Wessa M (2011) Loss of callosal fibre integrity in healthy elderly with age-related white matter changes. J Neurol 258:1451–1459. https://doi.org/10.1007/s00415-011-5956-6
Armstrong CL, Hunter JV, Ledakis GE (2002) Late cognitive and radiographic changes related to radiotherapy: Initial prospective findings. Neurology 59:40–48. https://doi.org/10.1212/wnl.59.1.40
Correa DD, DeAngelis LM, Shi W (2004) Cognitive functions in survivors of primary central nervous system lymphoma. Neurology 62:548–555. https://doi.org/10.1212/01.wnl.0000109673.75316.d8
Fujii O, Tsujino K, Soejima T (2006) White matter changes on magnetic resonance imaging following whole-brain radiotherapy for brain metastases. Radiat Med 24:345–350. https://doi.org/10.1007/s11604-006-0039-9
Chang EL, Wefel JS, Hess KR (2009) Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: A randomised controlled trial. Lancet Oncol 10:1037–1044. https://doi.org/10.1016/S1470-2045(09)70263-3
Monaco EA III, Faraji AH, Berkowitz O (2013) Leukoencephalopathy after whole-brain radiation therapy plus radiosurgery versus radiosurgery alone for metastatic lung cancer. Cancer 119:226–232. https://doi.org/10.1002/cncr.27504
Yamamoto M, Serizawa T, Shuto T, Akabane A, Higuchi Y, Kawagishi J (2014) Stereotactic radiosurgery for patients with multiple brain metastases(JLGK0901): a multi-institutional prospective eobservational study. Lancet Oncol 15:387–395. https://doi.org/10.1016/S1470-2045(14)70061-0
Baschnagel AM, Meyer KD, Chen PY, Krauss DJ, Olson RE, Pieper DR (2013) Tumor volume as a predictor of survival and local control in patients with brain metastases treated with Gamma Knife surgery. J Neurosurg 119:1139–1144. https://doi.org/10.3171/2013.7.JNS13431
Likhacheva A, Pinnix CC, Parikh NR, Allen PK, McAleer MF, Chiu MS (2013) Predictors of survival in contemporary practice after initial radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys 85:656–661. https://doi.org/10.1016/j.ijrobp.2012.05.047
Knoll MA, Oermann EK, Yang AI, PaydarI, Steinberger J, Collins B (2018) Survival of patients with multiple intracranial metastases treated with stereotactic radiosurgery: does the number of tumors matter? Am J Clin Oncol 41:425–431. https://doi.org/10.1097/COC.0000000000000299
Gorovets D, Ayala-Peacock D, Tybor DJ, Rava P, Ebner D, Cielo D (2017) Multi-institutional nomogram predicting survival free from salvage whole brain radiation after radiosurgery in patients with brain metastases. Int J Radiat Oncol Biol Phys 97:246–253. https://doi.org/10.1016/j.ijrobp.2016.09.043
Routman DM, Bian SX, Diao K, Liu JL, Yu C, Ye J (2018) The growing importance of lesion volume as a prognostic factor in patients with multiple brain metastases treated with stereotactic radiosurgery. Cancer Med 7:757–764. https://doi.org/10.1002/cam4.1352
Hatiboglu MA, Akdur K (2017) Evaluating critical brain radiation doses in the treatment of multiple brain lesions with Gamma Knife radiosurgery. Stereotact Funct Neurosurg 95:268–278. https://doi.org/10.1159/000478272
Tofilon PJ, Fike JR (2000) The radioresponse of the central nervous system: A dynamic process. Radiat Res 153:357–370. https://doi.org/10.1667/0033-7587(2000)153[0357:trotcn]2.0.co;2
Szerlip N, Rutter C, Ram N (2011) Factors impacting volumetric white matter changes following whole brain radiation therapy. J Neurooncol 103:111–119. https://doi.org/10.1007/s11060-010-0358-7
Beitinjaneh A, McKinney AM, Cao Q, Weisdorf DJ (2011) Toxic leukoencephalopathy following fludarabine-associated hematopoietic cell transplantation. Biol Blood Marrow Transplant 17(3):300–308. https://doi.org/10.1016/j.bbmt.2010.04.003
Coderre JA, Morris GM, Micca PL (2006) Late effects of radiation on the central nervous system: Role of vascular endothelial damage and glial stem cell survival. Radiat Res 166:495–503. https://doi.org/10.1667/RR3597.1
Beitinjaneh A, McKinney AM, Cao Q, Weisdorf DJ (2011) Toxic leukoencephalopathy following fludarabine-associated hematopoietic cell transplantation. Biol Blood Marrow Transplant 17(3):300-8. https://doi.org/10.1016/j.bbmt.2010.04.003
Coderre JA, Morris GM, Micca PL (2006) Late effects of radiation on the central nervous system: Role of vascular endothelial damage and glial stem cell survival. Radiat Res 166:495–503. https://doi.org/10.1667/RR3597.1

No competing interests reported.

SupplementaryTables.docx

Download PDF

Editorial decision: Major revision
29 Sep, 2022
Reviews received at journal
29 Sep, 2022
Reviews received at journal
14 Sep, 2022
Reviewers agreed at journal
12 Sep, 2022
Reviewers agreed at journal
07 Sep, 2022
Reviewers invited by journal
22 Aug, 2022
Editor assigned by journal
21 Aug, 2022
Submission checks completed at journal
21 Aug, 2022
First submitted to journal
21 Aug, 2022

You are reading this latest preprint version

Leukoencephalopathy in Patients with Brain Metastases Who Received Radiosurgery With or Without Whole Brain Radiotherapy

Status:

Version 1

Abstract

Figures

Introduction

Methods

Patient population

SRS treatment

Clinical presentation and neuroimaging assessments

Statistical analysis

Results

Clinical presentation

The Incidence of Leukoencephalopathy

Prognostic factors for leukoencephalopathy

Overall survival

Discussion

Study Limitations

Conclusions

Abbreviation

Declarations

References

Additional Declarations

Supplementary Files

Status:

Version 1